Information on results RFP 022896 – ANALYTICS AND FORMULATION OF mRNA WITH IMMUNOGENIC POTENTIAL

In connection with the co-financing of the project entitled „Development of novel mRNA/VLP-based vaccines against emerging zoonotic viral diseases” financed by the State budget from the Medical Research Agency (no. 2021 / ABM / 05 / 00001-00) as part of the Competition: Development of innovative therapeutic solutions using RNA technology, pursuant to § 8 sec. 2 point 2) of the co-financing agreement, Adamed Pharma S.A. informs that the contract will be awarded to the following companies that have presented the most advantageous offer:

• SyVento